Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases

• Published in: Journal of clinical oncology Vol. 27; no. 10; pp. 1572 - 1578
• Main Authors: RUSTHOVEN, Kyle E, KAVANAGH, Brian D, GASPAR, Laurie E, SCHEFTER, Tracey E, CARDENES, Higinia, STIEBER, Volker W, BURN, Stuart H, FEIGENBERG, Steven J, CHIDEL, Mark A, PUGH, Thomas J, FRANKLIN, Wilbur, KANE, Madeleine
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 01-04-2009
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Combined Modality Therapy; Dose Fractionation; Dose-Response Relationship, Radiation; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Kaplan-Meier Estimate; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Radiosurgery - adverse effects; Radiosurgery - methods; Tumors; Cancerology; Treatment; Phase II trial; Phase I trial; Digestive diseases; Hepatic disease; Stereotaxia; Malignant tumor; Radiotherapy; Liver metastasis; Cancer
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2008.19.6329

To evaluate the efficacy and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three hepatic metastases.
Patients with one to three hepatic lesions and maximum individual tumor diameters less than 6 cm were enrolled and treated on a multi-institutional, phase I/II clinical trial in which they received SBRT delivered in three fractions. During phase I, the total dose was safely escalated from 36 Gy to 60 Gy. The phase II dose was 60 Gy. The primary end point was local control. Lesions with at least 6 months of radiographic follow-up were considered assessable for local control. Secondary end points were toxicity and survival.
Forty-seven patients with 63 lesions were treated with SBRT. Among them, 69% had received at least one prior systemic therapy regimen for metastatic disease (range, 0 to 5 regimens), and 45% had extrahepatic disease at study entry. Only one patient experienced grade 3 or higher toxicity (2%). Forty-nine discrete lesions were assessable for local control. Median follow-up for assessable lesions was 16 months (range, 6 to 54 months). The median maximal tumor diameter was 2.7 cm (range, 0.4 to 5.8 cm). Local progression occurred in only three lesions at a median of 7.5 months (range, 7 to 13 months) after SBRT. Actuarial in-field local control rates at one and two years after SBRT were 95% and 92%, respectively. Among lesions with maximal diameter of 3 cm or less, 2-year local control was 100%. Median survival was 20.5 months.
This multi-institutional, phase I/II trial demonstrates that high-dose liver SBRT is safe and effective for the treatment of patients with one to three hepatic metastases.